Silo Pharma, Inc. (SILO)

NASDAQ: SILO · Real-Time Price · USD

1.210

-0.040 (-3.20%)

Mar 31, 2025, 9:53 AM EDT - Market open

Silo Pharma Employees

Silo Pharma had 3 employees as of December 31, 2023. The number of employees did not change compared to the previous year.

Employees

3

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

$24,034

Profits / Employee

-$1,464,293

Market Cap

5.43M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	0	-
Dec 31, 2022	3	1	50.00%
Dec 31, 2021	2	1	100.00%
Dec 31, 2020	1	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

SILO News

5 days ago - Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - GlobeNewsWire
4 weeks ago - Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment - GlobeNewsWire
5 weeks ago - Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - GlobeNewsWire
6 weeks ago - Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia - GlobeNewsWire
2 months ago - Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - GlobeNewsWire
3 months ago - Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - GlobeNewsWire
3 months ago - Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia - GlobeNewsWire
4 months ago - Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management - GlobeNewsWire